Highlight
The OCEANIC-STROKE trial investigated bleeding patterns associated with asundexian, a novel anticoagulant, in addition to antiplatelet therapy among patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). Key findings showed that asundexian significantly reduced ischemic strokes without a significant increase in major bleeding events compared to placebo. However, lower gastrointestinal bleeding incidence was higher with asundexian, primarily involving rectal bleeding. Importantly, bleeding rates were consistent across clinical subgroups, including those receiving dual antiplatelet therapy.
